Skip to main content
2023 AANS Annual Scientific Meeting Main banner
Back

Community Session

Tumor and Neuro Oncology Community

(NC5505) Endoscopic Approaches Are Associated with Superior Visual Outcomes: The Simpson Grade Is Irrelevant

Monday, April 24, 2023
8:25am – 8:41am PST
Location: Los Angeles Convention Center, 411- Theater
Disclosure(s):
Theodore H. Schwartz, MD: Elliquence: Royalty Recipient (Ongoing); Endostream Medical, Ltd: Ownership Interest (Ongoing); MIVI Neuroscience: Ownership Interest (Ongoing); Neurotechonology LLC: Stock Shareholder (excluding mutual funds) (Ongoing); Serenity Medical, Inc: Ownership Interest (Ongoing)
Gordon Li, MD: Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)
Chetan Bettegowda, MD, PhD: Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)